AbbVie (ABBV) Inventory (2012 - 2026)

AbbVie has disclosed Inventory across 15 years of filings, most recently posting $5.0 billion for Q1 2026.

• In Q1 2026, Inventory rose 11.56% year-over-year to $5.0 billion; the TTM figure through Mar 2026 stood at $5.0 billion (up 11.56% YoY), while the FY2025 annual figure was $5.0 billion, up 18.42% from the prior year.
• Inventory rose to $5.0 billion in Q1 2026, from $5.0 billion in the prior quarter.
• Over the last five years, Inventory for ABBV reached as high as $5.0 billion in Q1 2026 and fell as low as $3.2 billion in Q3 2022.
• The 5-year median for Inventory is $4.2 billion (2024), against an average of $4.2 billion.
• Annual changes were most pronounced in 2022 — Inventory advanced 0.3% — and 2023, when it advanced 25.5%.
• A 5-year view of Inventory shows it stood at $3.6 billion in 2022, then increased by 14.53% to $4.1 billion in 2023, then grew by 2.0% to $4.2 billion in 2024, then gained by 18.42% to $5.0 billion in 2025, then gained by 1.98% to $5.0 billion in 2026.
• According to Business Quant data, Inventory over the past three periods registered $5.0 billion, $5.0 billion, and $4.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.